[go: up one dir, main page]

PE20131165A1 - Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral - Google Patents

Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral

Info

Publication number
PE20131165A1
PE20131165A1 PE2013000530A PE2013000530A PE20131165A1 PE 20131165 A1 PE20131165 A1 PE 20131165A1 PE 2013000530 A PE2013000530 A PE 2013000530A PE 2013000530 A PE2013000530 A PE 2013000530A PE 20131165 A1 PE20131165 A1 PE 20131165A1
Authority
PE
Peru
Prior art keywords
fluorine substituted
antiviral treatment
halogen
alkyl
nucleosid
Prior art date
Application number
PE2013000530A
Other languages
English (en)
Inventor
Aesop Chop
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20131165A1 publication Critical patent/PE20131165A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (IV), DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES HALOGENO; R3, R4 Y R5 SON H, HALOGENO, N3, CN, NO2, ENTRE OTROS; n ES 0 A 2; R7 ES H, C(=O)R11, S(O)R11, ENTRE OTROS; R8 ES HALOGENO, N(R11)OR11, N3, NO, ENTRE OTROS; R9 ES H, HALOGENO, NO, NO2, ENTRE OTROS; R11 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), (c), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ARN POLIMERASA DEPENDIENTE DE ARN DEL VIRUS DE LA HEPATITIS C
PE2013000530A 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral PE20131165A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PE20131165A1 true PE20131165A1 (es) 2013-10-14

Family

ID=47748238

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2022003082A PE20230684A1 (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
PE2017001530A PE20171624A1 (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE2013000530A PE20131165A1 (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2022003082A PE20230684A1 (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
PE2017001530A PE20171624A1 (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral

Country Status (22)

Country Link
EP (1) EP2619206A1 (es)
JP (4) JP2013538230A (es)
KR (1) KR101879887B1 (es)
CN (1) CN103108876A (es)
AP (1) AP3699A (es)
AU (1) AU2011306066B2 (es)
BR (1) BR112013008017A2 (es)
CA (1) CA2807496C (es)
CL (1) CL2013000727A1 (es)
CO (1) CO6680669A2 (es)
CR (1) CR20130172A (es)
EA (1) EA026523B1 (es)
EC (1) ECSP13012560A (es)
IL (1) IL225221A0 (es)
MA (1) MA34593B1 (es)
MX (1) MX2013003179A (es)
NZ (1) NZ608070A (es)
PE (3) PE20230684A1 (es)
PH (1) PH12013500311B1 (es)
SG (1) SG188223A1 (es)
WO (1) WO2012039791A1 (es)
ZA (1) ZA201301042B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment
HRP20130862T1 (hr) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SI2595980T1 (sl) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
CN104230985B (zh) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
DK4204421T3 (da) 2020-08-27 2024-05-27 Gilead Sciences Inc Forbindelser og fremgangsmåder til behandling af virale infektioner
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023196975A1 (en) 2022-04-08 2023-10-12 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3256146A1 (en) * 2022-04-25 2025-07-03 Miracure Biotechnology Ltd NUCLEOSIDE MEDICINE FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION, AND ITS USE
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1296690A2 (en) 2000-02-18 2003-04-02 Shire Biochem Inc. METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
EP1539188B1 (en) * 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
ES2906207T3 (es) * 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ES2390188T3 (es) 2007-01-12 2012-11-07 Biocryst Pharmaceuticals, Inc. Análogos de nucleósidos antivirales
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
BRPI1013643A2 (pt) * 2009-02-10 2016-04-19 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment

Also Published As

Publication number Publication date
PH12013500311A1 (en) 2013-04-22
WO2012039791A1 (en) 2012-03-29
CL2013000727A1 (es) 2013-08-23
JP2019014726A (ja) 2019-01-31
PE20171624A1 (es) 2017-11-02
PE20230684A1 (es) 2023-04-21
CR20130172A (es) 2013-05-29
NZ608070A (en) 2015-11-27
JP2016074732A (ja) 2016-05-12
PH12013500311B1 (en) 2017-11-08
EP2619206A1 (en) 2013-07-31
BR112013008017A2 (pt) 2016-06-14
CN103108876A (zh) 2013-05-15
CA2807496A1 (en) 2012-03-29
JP2013538230A (ja) 2013-10-10
MA34593B1 (fr) 2013-10-02
AU2011306066B2 (en) 2015-01-29
AP2013006767A0 (en) 2013-03-31
SG188223A1 (en) 2013-04-30
IL225221A0 (en) 2013-06-27
AU2011306066A1 (en) 2013-02-28
KR20130110168A (ko) 2013-10-08
ECSP13012560A (es) 2013-06-28
KR101879887B1 (ko) 2018-07-18
EA201390141A1 (ru) 2013-09-30
ZA201301042B (en) 2014-07-30
CO6680669A2 (es) 2013-05-31
CA2807496C (en) 2019-01-22
JP2017119726A (ja) 2017-07-06
MX2013003179A (es) 2013-04-24
EA026523B1 (ru) 2017-04-28
JP6475280B2 (ja) 2019-02-27
AP3699A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20120995A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
CO6331439A2 (es) 1-2 bicíclicos pirimidinona carboxamida como inhibidores de la integrasa del virus de inmunodeficiencia humana
PE20140608A1 (es) Analogos de nucleotidos sustituidos
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
PE20171155A1 (es) Metodos y compuestos para tratar infecciones virales por paramyxoviridae
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PH12015501473A1 (en) Novel antiviral agents against hbv infection
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
CR10136A (es) Nucleósidos antivirales
PE20091236A1 (es) Derivados de pirimidina como immunomoduladores de tlr7
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
RU2010140627A (ru) Производные пирролидина
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
UY31538A1 (es) Inhibidores de la polimerasa virica
EA201591328A1 (ru) Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний

Legal Events

Date Code Title Description
FG Grant, registration